Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9676481 | 0.86 | CYP1A2 (0.47) | ALDH1A1MAPTLMNARAB9AKMT2A | |
| SCHEMBL2422430 | 0.85 | TPMT (0.48) | LMNARAB9ANPC1MAPK1 | |
| SCHEMBL358188 | 0.83 | PARP1 (0.49) | MAPK1 | |
| SCHEMBL3964444 | 0.83 | CA1 (0.47) | ALDH1A1MAPTPOLBGFERLMNA | |
| SCHEMBL26688582 | 0.81 | PLK1 (0.50) | ALDH1A1LMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL8132733 | 0.80 | KDM4E (0.44) | MAPTKMT2AGAA | |
| SCHEMBL358925 | 0.80 | ALDH1A1 (0.42) | ALDH1A1KMT2AMEN1SMN1; SMN2HPGD | |
| SCHEMBL3830003 | 0.80 | KMT2A (0.44) | ALDH1A1MAPTPOLBRAB9AKMT2A | |
| SCHEMBL4775443 | 0.78 | HSD17B2 (0.53) | ALDH1A1LMNARAB9AKMT2ANPC1 | |
| SCHEMBL8134192 | 0.78 | HSD17B3 (0.43) | ALDH1A1MAPTRAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1909910-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | claimed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| EP-0485984-B1 | Diarylmethoxypiperidine derivatives | UBE INDUSTRIES (JP) | 1996-04-24 | — | — | EP | claimed |
| US-5225559-A | DIARYLMETHOXYPIPERIDINE DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 1993-07-06 | — | — | US | claimed |
| US-5198449-A | N-substituted alpha-arylazacycloalkylmethanamines and their use as cardiovascular agents | A. H. ROBINS COMPANY INCORPORATED (US) | 1993-03-30 | — | — | US | claimed |
| EP-0485984-A2 | Diarylmethoxypiperidine derivatives | UBE INDUSTRIES, LTD. (JP) | 1992-05-20 | — | — | EP | claimed |
| CN-111285900-B | Coupling molecule DCZ0847 compound based on pterostilbene and apocynin, preparation method and application thereof | 上海市第十人民医院 | 2023-01-24 | — | — | CN | disclosed |
| CN-111285900-A | Coupling molecule DCZ0847 compound based on pterostilbene and apocynin, preparation method and application thereof | 上海市第十人民医院 | 2020-06-16 | — | — | CN | disclosed |
| CN-107365265-B | apocynin water-soluble prodrug, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2019-12-17 | — | — | CN | disclosed |
| CN-107365265-A | 4-hydroxy-3-methoxyacetophenone water-soluble prodrug, its preparation method, pharmaceutical composition and purposes | 中国科学院上海药物研究所 | 2017-11-21 | — | — | CN | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2468752-A1 | Thiazolopyridine derivatives as sirtuin-modulators | Sirtris Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| CN-1171788-A | Therapeutic agent for osteoporosis and triaza * compound | JAPAN TOBACCO INC (JP) | 1998-01-28 | — | — | CN | disclosed |
| EP-0485984-B1 | Diarylmethoxypiperidine derivatives | UBE INDUSTRIES (JP) | 1996-04-24 | — | — | EP | disclosed |
| US-5225559-A | DIARYLMETHOXYPIPERIDINE DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| US-5198449-A | N-substituted alpha-arylazacycloalkylmethanamines and their use as cardiovascular agents | A. H. ROBINS COMPANY INCORPORATED (US) | 1993-03-30 | — | — | US | disclosed |
| EP-0485984-A2 | Diarylmethoxypiperidine derivatives | UBE INDUSTRIES, LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
| US-4332805-A | FOR HUMAN AND VETERINARY MEDICINE | SANOFI (FR) | 1982-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | ALDH1A1 1903/4885MAPT 2184/4885POLB 2118/4885 |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | ALDH1A1 1825/4885MAPT 625/4885POLB 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.